LC–MS based assay to measure intracellular compound levels in Mycobacterium smegmatis: Linking compound levels to cellular potency  by Bhat, Jyothi et al.
Journal of Microbiological Methods 94 (2013) 152–158
Contents lists available at SciVerse ScienceDirect
Journal of Microbiological Methods
j ourna l homepage: www.e lsev ie r .com/ locate / jmicmethLC–MS based assay to measure intracellular compound levels in
Mycobacterium smegmatis: Linking compound levels to cellular potencyJyothi Bhat, Ashwini Narayan, Janani Venkatraman, Monalisa Chatterji ⁎
AstraZeneca India Pvt Ltd., Bellary Road, Hebbal, Bangalore 560024, India⁎ Corresponding author. Tel.: +91 806 621 3000; fax
E-mail address: monalisa.chatterji@astrazeneca.com
0167-7012 © 2013 The Authors. Published by Elsevier B
http://dx.doi.org/10.1016/j.mimet.2013.05.010a b s t r a c ta r t i c l e i n f oArticle history:
Received 11 March 2013
Received in revised form 7 May 2013
Accepted 14 May 2013






Antimycobacterial agentsDihydrofolate reductase (DHFR) plays a central role in maintaining cellular pool of tetrahydrofolic acid, a
cofactor necessary for DNA, RNA and protein synthesis. The clinical validation of DHFR as antibacterial target
was established by the success of trimethoprim (TMP). DHFR is also an attractive target for identifying
anti-tuberculosis molecules however, due to observed weak cellular potency, no DHFR inhibitors have
been developed as drugs so far. TMP and its analogs have poor cellular potency onMycobacterium tuberculosis
andMycobacterium smegmatis cells. We found a mutant strain ofM. smegmatis, mc2155 to be sensitive to TMP
whereas wild type strain was not inhibited by TMP. We utilized this system to probe if poor or lack of activity
of TMP is a consequence of poor intracellular compound levels. An LC–MS based method was developed for
measuring TMP and rifampicin (RIF) inM. smegmatis. Using the assay, equivalent RIF levels were observed in
both strains however, TMP was detected only in mc2155 cells, hence proving a positive correlation between
potency and compound levels. To the best of our knowledge this is the ﬁrst time LC–MS method has been
used to measure compound levels in mycobacterial cells. We propose it to be a valuable tool to understand
the lack of potency or resistance mechanisms in antimycobacterial drug development.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Reduced folate cofactors are required for the synthesis of a variety
of metabolites essential for cell viability. Most species can synthesize
folates de novo while higher vertebrates and some bacteria are also
able to utilize external preformed folates via the salvage pathway.
De novo synthesis of tetrahydrofolic acid starting from guanosine
triphosphate requires six enzymatic reactions (Hawser et al., 2006).
Dihydrofolate reductase (DHFR) catalyzes conversion of dihydrofolate
to THF and plays a central role in the maintenance of cellular pools of
THF and its derivatives. THF is essential for purine and thymidylate
synthesis hence, for cell growth and proliferation. It has been shown
that mutant cells that completely lack DHFR require glycine, a purine
and thymidine to grow (Ahmad et al., 1998; Urlaub and Chasin,
1980). Inhibition of DHFR underlies the mechanism of action of several
antibacterial, antimalarial and anticancer agents, such as methotrexate,
trimethoprim, pyrimethamine (Appleman et al., 1988; Burchall and
23Hitchings, 1965; Gorlick and Bertino, 1999; Huennekens, 1996;
Olliaro, 2000). The folate antagonists have proved to be an important: +91 802 362 1213.
(M. Chatterji).
.V. Open access under CC BY-NC-ND lclass of therapeutic compounds, as evidenced by their use as anti-
infective, anti-neoplastic, and anti-inﬂammatory drugs.
DHFR is a very well-conserved protein, yet sufﬁciently divergent to
permit inhibitors that selectively target bacterial enzymes over mam-
malian. Indeed, DHFR was discovered as a result of the search for the
therapeutic target of methotrexate, an anticancer drug (Huennekens,
1996). Trimethoprim, an important antibiotic, binds to bacterial
DHFRs >100 fold tighter than it does to vertebrate DHFRs (Burchall
and Hitchings, 1965). The antimalarial agent pyrimethamine targets
DHFR from Plasmodium falciparum (Appleman et al., 1988) but binds
weakly to mammalian enzyme. These species-selective agents exploit
the differences in the active site regions of the enzymes (Li et al.,
2000). Diaminopyrimidines e.g. TMP, brodimoprim, epiroprim, iclaprim
are potent inhibitors of bacterial DHFR. In themid-1970s TMPwas used
as monotherapy to treat urinary tract infections: however, it has been
used in combinationwith sulfamethaxazole (Dihydropteroate synthase
(DHPS) inhibitor) for the last three decades for the treatment of
uncomplicated forms of urinary tract infections as well as prophylaxis
and treatment of Pneumocystis carinii pneumonia in HIV patients
(Kielhofner, 1990). Iclaprim is presently in phase III clinical develop-
ment for skin and soft tissue infections.
DHFR and other enzymes of the folate pathway are well conserved
in Mycobacterium tuberculosis and other members of mycobacterial
genus. DHFR is an essential gene in M. tuberculosis, as well as, in
Mycobacterium smegmatis. However, no DHFR inhibitors have been
developed for tuberculosis therapy. Obtaining potent cellular activity
has been the challenge associated with DHFR inhibitors (Suling et al.,icense.
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against M. tuberculosis (Dosso et al., 2001) and interestingly was
found to be synergistic in combination with INH in vitro. Epiroprim
along with brodimoprim and dapsone (inhibitor of dihydropteroate
synthetase) has signiﬁcant activity on Mycobacterium leprae (Dhople,
1999). Epiroprim also shows activity against Mycobacterium avium
and Mycobacterium ulcerans, other pathogenic members of the myco-
bacterial genus (Dhople, 2000; Locher et al., 1996).WR99210, a triazine
DHFR inhibitor has been reported to have signiﬁcant in vitro activity
againstM. tuberculosis (Gerum et al., 2002) however, under our exper-
imental conditions the activity was found to beweak (data not shown).
A recent HTS campaign identiﬁed NC00094221, a diaminoquinazoline
which inhibits M. tuberculosis DHFR activity and has MIC of 207 μM
for wildtype laboratory strain H37Rv (Kumar et al., 2012). The weak
cellular potency of DHFR inhibitors might be due to lack of sufﬁcient in-
tracellular drug concentration or due to DHFR/folate biosynthesis path-
way being less vulnerable. In this study, we want to understand if weak
cellular activity is related to compound levels in the cell. M. smegmatis
mc2155 sensitivity to TMP provided us with a model system to address
this question.
OriginallyM. smegmatismc2155was identiﬁed as a high transforming
mutant strain derived from the WTM. smegmatis (Snapper et al., 1990).
Subsequent study demonstrated that the strain has changes in the cell
envelop namely, lack of polar glycolipids and differences in distribution
of phospholipids and glycolipids among outermost and deeper layers
of cell envelope (Etienne et al., 2005). It is not absolutely established
whether the changes in cell envelope are responsible for high transfor-
mation and other phenotypes e.g. smooth phenotype, lack of clumping
and greater uptake of chenodeoxycholate. The mechanism/s underlying
these changes is/are not fully understood.
Most studies addressing compound accumulation in bacterial cells
use either radioactive or ﬂuorescent derivatives of the compounds. In
this study we have developed an LC–MS based assay to estimate the
compound levels in cells. The assay provides the advantage of working
with un-labeled molecule without compromising on sensitivity and
speciﬁcity. The LC–MS approach has not been reported previously with
mycobacterial systems. A previous study with Pseudomonas aeruginosa
does use LC–MS assay (Cai et al., 2009) along with other methods. We
have designed our assay to be more stringent with respect to discrimi-
nating between non-speciﬁc compound binding to the cell versus
compound inside a cell. Using the assaywehave demonstrated a positive
correlation between TMP potency and intracellular compound concen-
tration. We believe that this assay will serve as a useful tool in under-
standing translation of enzyme inhibition to cellular potency, and
resistance mechanisms.
2. Materials and methods
2.1. Reagents
All reagents and organic solvents were purchased from Sigma-
Aldrich (St. Louis, MO. USA), except ammonium formate and acetoni-
trile which were purchased from Fluka and J.T.Baker respectively.
Gemini C-18 column (50 mm × 4.6 mm (5 mm × 110 Å)) was pro-
cured from Phenomenex Inc., Torrance, CA, USA. Reversed-phase HPLCTable 1
MIC in Msm ATCC607, mc2155 and DHFR over-expression strains.
Compounds MIC (μg/ml)
Msm ATCC607 Msm mc2155 mc2155 + vecto
Without Kan
Trimethoprim >32–>256 4 4–8
Isoniazid 0.5–1 1–2 1–2
Rifampicin 16 4–8 4–8was performed using Agilent-1200series HPLC system (Agilent Technol-
ogies Inc., Santa Clara, USA) equipped with a temperature-controlled
96-well-plate autosampler. Mass spectrometrywas performed using Ac-
curate Mass Q-TOF 6520 from Agilent (Agilent Technologies Inc., Santa
Clara, USA).
2.2. Bacterial strains and growth
M. smegmatis mc2155 and M. smegmatis ATCC607 strains were
grown in Middlebrook 7H9 broth (BD Diagnostics, Sparks, MD)
containing 10% ADC (Albumen-Dextrose-Catalase), 0.2% glycerol, and
0.05% Tween 80 at 37 °C. Cloning and plasmid preparations were
performed in Escherichia coli DH5α. Kanamycin was used for selection
at a concentration of 20 μg/ml.
2.3. Cloning of M. tuberculosis dhfr gene in pMV261
M. tuberculosis DHFR over-expression construct was generated
by amplifying the dhfr gene (500 bp in length) using the primers
Tdfr261F/Tdfr261R (Primer sequences are: Tdfr261F—ATCTGAATTCA
TGGTGGGGCTGATC and Tdfr261R—AGATAAGCTTTCATGAGCGGTGGT
AGCTG). M. tuberculosis genomic DNA was used as the template and
high ﬁdelity Taq DNA polymerase (Phusion, Finnzyme) was used for
ampliﬁcation. The PCR fragment was cloned in pMV261 (EcoRI–
HindIII sites) under the control of the Hsp60 constitutive promoter
to obtain pBAN0406. The sequence of the cloned dhfr gene was
conﬁrmed by sequencing (Microsynth, Switzerland). Vector pMV261
and recombinant plasmid were transformed into M. smegmatis
mc2155 using electroporation (Wards and Collins, 1996). The strain
over-expressing DHFR was used for MIC modulation studies.
2.4. Minimal inhibitory concentration (MIC) measurement
MIC was determined by broth microdilution method and was
deﬁned as inhibitor concentration that led to >80% growth inhibition
of the treated culture compared to untreated control. The experiment
was performed at cell densities of 105 cfu/ml and treated with various
drug concentrations in 96 well plates. The plates were incubated for
72 h at 37 °C post drug treatment. The cell growth was monitored
by measuring absorbance at 600 nm. Control cultures were treated
with equivalent amount of DMSO as present in treated cultures.
2.5. Preparation of cell extracts
M. smegmatismc2155 or ATCC607 were grown in 200 ml of media
in a 1 l ﬂask with rotation at 200 rpm for 16 h. At OD600 of 0.3, the
culture was split into four different ﬂasks (50 ml each in 250 ml
ﬂasks) namely — test, untreated control, wash control and process
control. Test ﬂask was treated with the test compound and grown
for another 4 h at 37 °C. Equal amount of DMSO was added for the
untreated control, while equal amount of compound was added just
before harvesting for the wash control. At the end of 4 h treated
cells and controls were harvested by centrifuging at 6000 g
for 10 min. Harvested cells were washed two times with 7H9
media without ADC and once with Milli-Q-water. An equivalentr mc2155 + vector mc2155 + DHFR mc2155 + DHFR




154 J. Bhat et al. / Journal of Microbiological Methods 94 (2013) 152–158concentration of compound (115 μg of TMP for both ATCC607 and
mc2155, 480 μg of RIF for ATCC607 and 240 μg of RIF for mc2155)
was added just before extract preparation to the process control.
The washed cells were resuspended in 3 ml of methanol:chloroform:
water (12:5:3), warmed at 65 °C for 20 min and stored at −20 °CFig. 1. LC–MS analysis of TMP and RIF treated cell extracts and controls. Extracted ion chroma
ed Msm mc2155 at m/z = 291–292. B) Extracted ion chromatogram of TMP treated Msm AT
at m/z = 823–824. D) Extracted ion chromatogram of RIF treated Msm ATCC607 at m/z =
also observed. The ESI scan of this peak showed that it contained RIF signals along with sig
not be attributed to any known adducts of RIF.overnight. Unlysed cell debris was removed by centrifuging at
12500 g for 15 min. The supernatant was collected and 250 μl of
water was added to every ml of the supernatant. This mixture was
vortexed well, centrifuged at 12500 g for 20 min. The supernatant
was collected and dried using a vacuum manifold. The dried pellettogram contains TMP/RIF speciﬁc signals. A) Extracted ion chromatogram of TMP treat-
CC607 at m/z = 291–292. C) Extracted ion chromatogram of RIF treated Msm mc2155
823–824. In RIF treated extract in addition to RIF signal a small peak at RT = 8.14 was
nals corresponding to higher molecular mass (e.g. 923.43, 955.45, 977.44). These could
Fig. 1 (continued).
155J. Bhat et al. / Journal of Microbiological Methods 94 (2013) 152–158was re-dissolved in 300 μl of 10 mM ammonium formate (pH = 6.3)
and extractedwith 600 μl of ethyl acetate. The organic layerwas collect-
ed by centrifuging at 12500 g for 10 min and dried as before. The dried
pellets were reconstituted in HPLC buffer on the day of analysis.2.6. Optimized LC–MS conditions for RIF and TMP
For analysis of TMP, an isocratic gradient with 10 mM ammonium
formate buffer (pH = 6.3) as mobile phase A and acetonitrile as
Table 2
Amount of intracellular compounds detected.
Amount of TMP
detected (pmol)
Stdev Amount of RIF
detected (pmol)
Stdev
ATCC607 wash control 1.0 1.0 4.7 0.0
ATCC607 treated 1 0.9 68 10.0
mc2155 wash control 2.0 2.9 0.5 0.0
mc2155 treated 23 8.4 68 14.0
156 J. Bhat et al. / Journal of Microbiological Methods 94 (2013) 152–158mobile phase B was used at a ﬂow rate of 0.5 ml/min with a run time
of 10 min. For RIF analysis, a binary gradient with 10 mM ammonium
formate (pH = 6.3) as solvent B and acetonitrile as solvent A was
used. The gradient applied for separation was kept at 95% B for the
ﬁrst 2 min., and then decreased to 15% B in the next 8 min. This
level was held for 5 min before increasing once again to 95% B during
the next 12 min. The ﬂow rate was 0.5 ml/min with the run time of
20 min. All the chromatographic measurements were performed at
room temperature and the autosampler was maintained at 4 °C. The
quantitation was achieved by MS detection in positive mode. The op-
timized MS parameters for TMP were — gas temperature of 350 °C,
gas ﬂow of 8 l/min, and nebulizer gas pressure of 35 psi. Capillary
voltage was set at 3500 V, fragmentor voltage was 150 V, skimmer
voltage at 65 V and octopole RF peak voltage of 750 V. Data acquisi-
tion range used was 200–500 m/z. For MS analysis of RIF, gas temper-
ature of 300 °C, gas ﬂow of 10 l/min, and nebulizer gas pressure of
40 psi was used. Capillary voltage was maintained at 3500 V,
fragmentor voltage was 150 V, skimmer voltage at 65 V and octopole
RF peak voltage of 750 V. For data acquisition,m/z range of 300–1000
was used. The lower limit of detection (S/N > 10) and lower limit of
quantitation (S/N > 30) was determined for both RIF and TMP.
Calibration curveswere acquired by plotting the observed compound
concentration against the known concentration loaded. The concentra-
tions injected were in the range of 0.41–100 pmol for TMP and
8–125 pmol for RIF. The data was ﬁtted to linear regression analysis.
Calibration curves were acquired by plotting the peak area against
the nominal concentration of TMP and RIF using a linear plot. The
amount of drug present in the sample (x) was calculated using the
formula Y = mx + C, where Y is the estimated concentration of the
drug, m is the slope of the calibration curve, C is a constant obtained
by the calibration curve.
The criterion for accepting each back-calculated standard concen-
tration was ±15% deviation from the known value and S/N ratio of
more than 10. Limit of quantitation (S/N ratio of >30) of TMP is
~1.23 pmol and limit of detection (S/N ratio of >10) of TMP is
0.41 pmol. For RIF both limit of quantitation and lower limit of detec-
tion was 8 pmol.
3. Results
3.1. Potency of TMP on M. smegmatis strains
Antimicrobial activity of TMP was determined for two strains of
M. smegmatis (ATCC607 and mc2155). MIC of TMP for M. smegmatis
mc2155 was observed to be 4 μg/ml, while TMP was inactive on
ATCC607 strain. TMP is known to act by inhibition of DHFR enzyme, to
conﬁrm that DHFR is the target of TMP inM. smegmatis, and MIC modu-
lation upon target over-expressionwas estimated.M. smegmatismc2155
was transformed with the plasmid containing dhfr under the Hsp60
constitutive promoter. MIC was estimated for M. smegmatis cells
transformed with vector or DHFR-expressing plasmid (Table 1). The
MIC forM. smegmatismc2155 containing vector was similar to the strain
alone (4–8 μg/ml). However, the MIC for cells over-expressing DHFR in-
creased by at least 4 fold (>32 μg/ml) as compared to the vector control.
TheMIC valueswere not affected by the presence or absence of kanamy-
cin (Kan) in the media, kanamycin being the selection marker for the
over-expression plasmid. The MIC values for other inhibitors like isonia-
zid and RIF remained unaffected. The signiﬁcant increase in MIC values
for TMP in DHFR over-expressing strain indicates that TMP inhibits
DHFR inM. smegmatis.
3.2. TMP levels in M. smegmatis strains
To understand the observed differential MIC of TMP between the
two strains of M. smegmatis, TMP was estimated in cell extracts of
treated and untreated cells by LC–MS. RIF, which has similar MICsfor the two strains served as a positive control for the assay. Prior to
the estimation of cellular levels, TMP and RIF were subjected to
MS/MS and ESI fragmentation (TMP 291 > 230 and RIF 823.3 > 791)
to assess the fragmentation pattern. Under our experimental condi-
tions, TMP eluted at 4.6 min whereas RIF eluted at 8.6 min. Amount
of TMP and RIF in the cell extracts was estimated using the standard
curve as described in Materials and methods section 2.6.
In every experiment, one culture was treated with the compound
(10× of MIC concentrations for TMP or 5× of MIC concentrations for
RIF) and continued to grow for another 4 h at 37 °C (test culture).
Untreated control, wash control and process control were processed
in parallel. Wash control wherein equivalent amount of compound
as test culture was added prior to harvesting, enabled estimation of
the amount of drug non-speciﬁcally sticking to the cells post washing.
While process control, wherein known amount of drug was added
after washing, enabled estimation of the relative recovery for each
extraction. The approach of treating 107 cfu/ml cells with high dose
of compound for a short duration (4 h) was followed to enable
detectable levels of compound, without triggering cell death. In com-
parison, MIC is determined by treating 105 cfu/ml cells for 72 h.
Representative chromatograms of various samples used in the
study are as shown in Fig. 1. For TMP, there were no signiﬁcant
drug levels in untreated controls and in wash controls showing that
non-speciﬁc binding of the compound to the cells was minimal. In
TMP treated M. smegmatis mc2155 extracts, the relative levels of
TMP was 11 fold higher compared to the wash control (Table 2).
Whereas in TMP treated ATCC607 cell extract, TMP could not be
detected. The treated and wash controls were comparable to
untreated sample (Fig. 2A). The process control behaved similarly
for both strains with percentage recovery ranging from 1–6% for
mc2155 and 1–13% for ATCC607. The scenario for RIF was different
from that of TMP, similar levels of the drug was found in treated
cell extracts of both strains, in line with their equivalent MIC for
both strains (Fig. 2B).
Further to understand the kinetics of compound concentration in
the cell, a time course study was performed by treating the cells
with TMP for different durations (1, 2, and 4 h for mc2155; 4 and
8 h for ATCC607). Extract preparation and analysis of the extract
was done as above. Wash control, process control and untreated con-
trols were used in each case. In the case of M. smegmatis mc2155 the
amount of TMP steadily increased with the increase in time (Fig. 3).
However, no TMP was detected in ATCC607 cells even 8 h post
treatment.
4. Discussion
As reported in the literature, poor cellular activity was observed
for diaminopyrimidines speciﬁcally TMP for mycobacterial strains.
TMP did not show MIC against M. tuberculosis H37Rv (>256 μg/ml)
and M. smegmatis ATCC607 (>32 μg/ml). M. smegmatis mc2155, is
an efﬁcient plasmid-transformation (ept) mutant strain isolated
from wild-type ATCC607 (Snapper et al., 1990). As discussed above
the mutant strain was sensitive to TMP. M. smegmatis mc2155 has
been shown to have changes in the cell envelope speciﬁcally with re-
spect to lipid composition of the cell envelope (Etienne et al., 2005).












































Fig. 2. Levels of TMP (A) and RIF (B) in Msm extracts. The cells are treated with 10
times MIC concentration for TMP and 5 times MIC concentration for RIF. The cells
were washed to remove the non-speciﬁc inhibitors that may be binding to the cell.
The intracellular concentration was measured by lysing the cells and quantitating the
amount of inhibitor by LC–MS. The wash controls were included to assess the amount
of non-speciﬁc drug binding to the bacterial cells.
157J. Bhat et al. / Journal of Microbiological Methods 94 (2013) 152–158hypothesized that mc2155 and its wild type ATCC607 strains could
have different levels of TMP in the cells.
The reported approaches used for assessing intracellular compound
concentrations are radioactively labeled compound (e.g. rifampicin and
nalidixic acid) (Mortimer and Piddock, 1991; Williams and Piddock,
1998) or utilizing the intrinsic ﬂuorescence of quinolones (Piddock et




















Fig. 3. Time dependent increase in TMP levels in Msm extracts. Msm mc2155 (•) were
treated for 1, 2 and 4 h and Msm ATCC607 (■) was treated for 4 and 8 h. The intracel-
lular TMP concentration was plotted against the time of treatment. In the case of
mc2155 the TMP levels increased with increase in time. The graph is extrapolated to
8 h from the available data up to 4 h. In ATCC607 extract no signiﬁcant levels of TMP
was observed even after 8 h of treatment.Compound accumulation for quinolones and ﬂuoroquinolones has
been extensively studied using the ﬂuorescence method in various
bacteria e.g. P. aeruginosa, Staphylococcus aureus, E. coli, Streptococcus
pneumoniae, and Bacteroides fragilis. Quinolone and ﬂuoroquinolone ac-
cumulation has also been established bymodiﬁed ﬂuorescence method
in mycobacterium (Piddock and Ricci, 2001; Williams et al., 1998).
Above approaches involve washing of drug treated cells with buffer
prior to cell lysis. It has been considered that washing of cells with
buffer might lead to leaching of compound from the cell. An alternate
methodology which avoids washing the cell is the silicon oil method.
In this method, the treated drug cells are centrifuged through silicon
oil (Moreau et al., 1984; Li et al., 1994). Published results wherein the
two methodologies were compared show that higher levels of RIF and
ﬂuoroquinolones were detected by silicon oil method (Williams and
Piddock, 1998; Williams et al., 1998).
An HPLC based method for detection of linezolid cellular levels in
E. coli, Citrobacter freundii and Enterobacter aerogenes has been reported
(Schumacher et al, 2007). Further LC–MS based detection was carried
out for ciproﬂoxacin accumulation in P. aeruginosa and compared with
the radioactive and ﬂuorescence methods (Cai et al., 2009). The major
advantage of LC–MS is that it allows estimation of non-radioactive
and non-ﬂuorescent native molecule. Also, the sensitivity and speciﬁci-
ty is retained due to the use of mass spectrometry. The sensitivity can
further improved by using a well deﬁned HPLC method and infusing
matrix-effect-free chromatogram for the analysis. In this study, we
have developed and used an LC–MS assay to detect TMP levels in
M. smegmatis. We have also followed washing of drug treated cells
with buffer prior to lysis. In addition we have included a wash control
to estimate the extent of non-speciﬁc binding. The use of the method
might be challenging for compounds a) that are highly potent hence,
intracellular levels below the limit of detection, b) that are metabolized
in the cell c) that are undetectable due to poor ionization or d) that have
unsolvable matrix interference.
We propose that the assay can be used for understanding intracellu-
lar concentration of compounds; for addressing questions related to
drug accumulation, lack of cellular potency and resistance mechanism.
In the future, we will like to adapt the methodology to M. tuberculosis.
This study using surrogateM. smegmatis provides the sound validation
for using LC–MS based method to detect compound levels in the cell.
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